drugset / Trial / NCT05471063
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
Unknown
30 enrolled
Peking Union Medical College Hospital
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of ABCD in the treatment of cryptococcal meningitis in non-HIV patients at week 4, the end of induction therapy, week 10 and the end of consolidation therapy.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2023-02-28
- Completion
- 2023-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B Colloidal Dispersion | Unknown | 3 mg/kg | — |
| Subject | Amphotericin B Colloidal Dispersion | Unknown | 4 mg/kg | — |
| Subject | Fluconazole | Small molecule | 400 mg | — |
| Subject | Fluconazole | Small molecule | 600 mg | — |
| Subject | Flucytosine | Small molecule | 100 mg/kg | — |